Selected disorder	Analysis	Prevalence (%)	95%CI (%)	95%PI (%)	I2 (%)	95%CI (%)
PTSD	Main analysis	12.53	7.59–20.00	1.22–62.41	98.6	98.3–98.9
	Special population removed	14.98	3.59–45.49	0.23–93.16	99.4	99.2–99.5
	Non-validated tools removed	11.31	6.99–17.80	1.32–54.98	98.5	98.2–98.8
	Outliers and influential cases removed	9.74	6.87–13.62	2.99–27.39	89.7	83.6–93.5
	Screening tools removed	8.96	5.21–14.99	2.01–32.05	92.8	86.3–96.3
Depression	Main analysis	15.27	9.92–22.78	0.97–76.80	99.1	99.0–99.2
	Special population removed	13.76	6.17–27.91	0.34–88.07	99.4	99.3–99.5
	Non-validated tools removed	13.56	9.04–19.85	1.15–67.93	99.0	98.9–99.1
	Outliers and influential cases removed	15.14	10.30–21.69	1.63–65.72	97.9	97.5–98.2
	Screening tools removed	7.73	3.54–16.05	0.40–63.63	97.6	96.9–98.2
ADHD	Main analysis	6.55	4.61–9.23	1.20–28.76	98.3	98.0–98.6
	Special population removed	6.58	4.33–9.88	1.18–29.32	98.7	98.5–99.0
	Non-validated tools removed	6.53	4.35–9.69	1.03–31.94	98.5	98.2–98.8
	Outliers and influential cases removed	6.35	5.10–7.87	3.13–12.46	80.8	68.2–88.5
	Screening tools removed	4.82	2.38–33.02	0.52–33.02	93.6	90.0–95.9
Anxiety	Main analysis	11.78	7.27–18.54	1.10–61.61	98.0	97.6–98.4
	Special population removed	10.49	4.39–23.05	0.55–71.43	98.5	98.0–98.8
	Non-validated tools removed	11.44	6.89–18.40	1.00–62.20	98.1	97.6–98.4
	Outliers and influential cases removed	15.19	10.42–21.63	2.70–53.59	97.5	96.8–98.0
	Screening tools removed	10.60	4.54–22.82	0.40–77.69	98.3	97.8–98.6
Conduct disorder	Main analysis	9.76	4.93–18.41	0.79–59.54	97.8	97.1–98.3
	Special population removed	12.07	5.08–26.06	0.92–66.92	98.1	97.3–98.7
	Non-validated tools removed	9.79	4.57–19.72	0.65–64.15	97.9	97.2–98.4
	Outliers and influential cases removed	9.91	4.82–19.28	0.97–55.13	93.9	90.5–96.1
	Screening tools removed	3.43	0.65–16.13	0.02–84.03	95.0	90.1–97.4

Note: This table displays the results of sensitivity analyses that were conducted to assess heterogeneity after the removal of studies that included special population(s) or non-validated tools, outliers and influential cases and screening tools, respectively. Heterogeneity remains high (I² > 80%) despite the removal of the above-mentioned studies across all conditions.